Dr. Dana Binyamin is a microbiome researcher specializing in host-microbe interactions, with a focus on how microbial communities influence human health and disease. She was born and raised in Tiberias, Israel, and currently lives with her husband and their three daughters in California, where she is pursuing her postdoctoral research.

 

During her undergraduate studies, she trained in a microbiology lab, gaining her first hands-on research experience while studying antibiotic resistance in Helicobacter pylori at the Tzafon Medical Center microbiology laboratory. This experience sparked her interest in scientific research and shaped her decision to pursue a research career.

 

She continued her academic training at the Azrieli Faculty of Medicine at Bar-Ilan University, where she completed her master’s degree under the supervision of Prof. Avi Peretz and Prof. Omry Koren. Her research focused on Clostridium difficile and antibiotic resistance, later expanding to broader questions surrounding microbial communities and the gut microbiome.

 

She then joined Prof. Omry Koren’s lab for her Ph.D., where she studied how the gut microbiota influences aging and host physiology, including its effects on metabolic processes. In parallel, she investigated microbiome dynamics in pregnant women with inflammatory bowel disease, examining host–microbiome interactions and potential implications for disease susceptibility in their children. Her Ph.D. was supported by the Adams Fellowship Program of the Israel Academy of Sciences and Humanities.

 

As a postdoctoral researcher in the Department of Pathology at Stanford University School of Medicine, Binyamin focuses on understanding the ways in which the microbiome influences host physiology and disease. Building on her background in microbiome research, she investigates how microbial communities and their metabolites affect metabolic, immune, and disease-related pathways. Her long-term scientific goal is to uncover microbiome-driven mechanisms that can be translated into targeted therapeutic strategies, advancing disease prevention and improving health through precision microbiome interventions.